Is TC BioPharm Stock a Good Investment?
TC BioPharm Investment Advice | TCBPW |
- Examine TC BioPharm's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research TC BioPharm's leadership team and their track record. Good management can help TC BioPharm navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact TC BioPharm's business and its evolving consumer preferences.
- Compare TC BioPharm's performance and market position to its competitors. Analyze how TC BioPharm is positioned in terms of product offerings, innovation, and market share.
- Check if TC BioPharm pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about TC BioPharm's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in TC BioPharm plc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if TC BioPharm plc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine TC BioPharm Stock
Researching TC BioPharm's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.75. TC BioPharm plc had not issued any dividends in recent years. The entity had 1:50 split on the 21st of November 2022.
To determine if TC BioPharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding TC BioPharm's research are outlined below:
| TC BioPharm plc generated a negative expected return over the last 90 days | |
| TC BioPharm plc has high historical volatility and very poor performance | |
| TC BioPharm plc has some characteristics of a very speculative penny stock | |
| TC BioPharm plc has a very high chance of going through financial distress in the upcoming years | |
| TC BioPharm plc has accumulated 1.8 M in total debt. TC BioPharm plc has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TC BioPharm plc has accumulated about 1.55 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| TC BioPharm plc has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: TC Biopharm Plans to Outsource Functions, Reduce Workforce -March 18, 2025 at 0851 am EDT - Marketscreener.com |
TC BioPharm Quarterly Cash And Short Term Investments |
|
TC BioPharm's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (3.92) | (4.11) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (2.53) | (2.40) |
Determining TC BioPharm's profitability involves analyzing its financial statements and using various financial metrics to determine if TC BioPharm is a good buy. For example, gross profit margin measures TC BioPharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of TC BioPharm's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in TC BioPharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TC BioPharm plc. Check TC BioPharm's Beneish M Score to see the likelihood of TC BioPharm's management manipulating its earnings.
Evaluate TC BioPharm's management efficiency
The company has return on total asset (ROA) of (0.982) % which means that it has lost $0.982 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.7704) %, meaning that it generated substantial loss on money invested by shareholders. TC BioPharm's management efficiency ratios could be used to measure how well TC BioPharm manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2025. Return On Capital Employed is likely to drop to -4.11 in 2025. At this time, TC BioPharm's Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to climb to about 4.9 M in 2025, whereas Total Assets are likely to drop slightly above 10 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | -3.3 K | -3.4 K | |
| Price Book Value Ratio | 82.59 | 86.71 | |
| Enterprise Value Multiple | (16.25) | (17.06) | |
| Price Fair Value | 82.59 | 86.71 | |
| Enterprise Value | 56.7 B | 53.8 B |
Effective leadership at TC BioPharm drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.012 |
Basic technical analysis of TCBPW Stock
As of the 22nd of March, TC BioPharm owns the standard deviation of 17.39, and Market Risk Adjusted Performance of 1.05. In connection with fundamental indicators, the technical analysis model makes it possible for you to check timely technical drivers of TC BioPharm plc, as well as the relationship between them. Please validate TC BioPharm plc standard deviation, as well as the relationship between the value at risk and kurtosis to decide if TC BioPharm plc is priced adequately, providing market reflects its prevailing price of 0.006 per share. As TC BioPharm plc appears to be a penny stock we also recommend to double-check its total risk alpha numbers.TC BioPharm's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TC BioPharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on TC BioPharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases TC BioPharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Randall Mark Edward over a month ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 |
Understand TC BioPharm's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing TC BioPharm's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0857 | |||
| Market Risk Adjusted Performance | 1.05 | |||
| Mean Deviation | 11.95 | |||
| Semi Deviation | 11.79 | |||
| Downside Deviation | 13.04 | |||
| Coefficient Of Variation | 1164.53 | |||
| Standard Deviation | 17.39 | |||
| Variance | 302.54 | |||
| Information Ratio | 0.0895 | |||
| Jensen Alpha | 1.59 | |||
| Total Risk Alpha | 2.9 | |||
| Sortino Ratio | 0.1193 | |||
| Treynor Ratio | 1.04 | |||
| Maximum Drawdown | 102.24 | |||
| Value At Risk | (23.13) | |||
| Potential Upside | 31.3 | |||
| Downside Variance | 170.14 | |||
| Semi Variance | 138.92 | |||
| Expected Short fall | (15.52) | |||
| Skewness | 1.45 | |||
| Kurtosis | 4.25 |
| Risk Adjusted Performance | 0.0857 | |||
| Market Risk Adjusted Performance | 1.05 | |||
| Mean Deviation | 11.95 | |||
| Semi Deviation | 11.79 | |||
| Downside Deviation | 13.04 | |||
| Coefficient Of Variation | 1164.53 | |||
| Standard Deviation | 17.39 | |||
| Variance | 302.54 | |||
| Information Ratio | 0.0895 | |||
| Jensen Alpha | 1.59 | |||
| Total Risk Alpha | 2.9 | |||
| Sortino Ratio | 0.1193 | |||
| Treynor Ratio | 1.04 | |||
| Maximum Drawdown | 102.24 | |||
| Value At Risk | (23.13) | |||
| Potential Upside | 31.3 | |||
| Downside Variance | 170.14 | |||
| Semi Variance | 138.92 | |||
| Expected Short fall | (15.52) | |||
| Skewness | 1.45 | |||
| Kurtosis | 4.25 |
Consider TC BioPharm's intraday indicators
TC BioPharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of TC BioPharm stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
TC BioPharm time-series forecasting models is one of many TC BioPharm's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary TC BioPharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
TCBPW Stock media impact
Far too much social signal, news, headlines, and media speculation about TC BioPharm that are available to investors today. That information is available publicly through TCBPW media outlets and privately through word of mouth or via TCBPW internal channels. However, regardless of the origin, that massive amount of TCBPW data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of TC BioPharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of TC BioPharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to TC BioPharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive TC BioPharm alpha.
TC BioPharm Corporate Management
| Michael MBA | CoFounder Chairman | Profile | |
| Lauren Bor | Head Division | Profile | |
| Martin Thorp | CFO Director | Profile | |
| Christopher Camarra | Executive Communications | Profile | |
| Bryan Kobel | CEO Director | Profile | |
| Angela Scott | CoFounder COO | Profile |
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.